JP2022540877A - Ｃｍｖ感染に関連する疾患の治療のための融合毒素タンパク質 - Google Patents

Ｃｍｖ感染に関連する疾患の治療のための融合毒素タンパク質 Download PDF

Info

Publication number
JP2022540877A
JP2022540877A JP2022502075A JP2022502075A JP2022540877A JP 2022540877 A JP2022540877 A JP 2022540877A JP 2022502075 A JP2022502075 A JP 2022502075A JP 2022502075 A JP2022502075 A JP 2022502075A JP 2022540877 A JP2022540877 A JP 2022540877A
Authority
JP
Japan
Prior art keywords
immunotoxin
seq
fold
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022502075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022540877A5 (https=
Inventor
ニッケ クレダル，トーマス，
ローゼンキルデ，メッテ，マリエ
Original Assignee
ケブンハウン ユニヴェルスィテイト
ダンマークス テクニスケ ウニヴェルシテート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケブンハウン ユニヴェルスィテイト, ダンマークス テクニスケ ウニヴェルシテート filed Critical ケブンハウン ユニヴェルスィテイト
Publication of JP2022540877A publication Critical patent/JP2022540877A/ja
Publication of JP2022540877A5 publication Critical patent/JP2022540877A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022502075A 2019-07-12 2020-06-25 Ｃｍｖ感染に関連する疾患の治療のための融合毒素タンパク質 Pending JP2022540877A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19186000 2019-07-12
EP19186000.6 2019-07-12
PCT/EP2020/067785 WO2021008840A1 (en) 2019-07-12 2020-06-25 Fusion toxin proteins for treatment of diseases related to cmv infections

Publications (2)

Publication Number Publication Date
JP2022540877A true JP2022540877A (ja) 2022-09-20
JP2022540877A5 JP2022540877A5 (https=) 2023-06-12

Family

ID=67437717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502075A Pending JP2022540877A (ja) 2019-07-12 2020-06-25 Ｃｍｖ感染に関連する疾患の治療のための融合毒素タンパク質

Country Status (10)

Country Link
US (1) US20220281933A1 (https=)
EP (1) EP3997107A1 (https=)
JP (1) JP2022540877A (https=)
KR (1) KR20220032610A (https=)
CN (1) CN114206944A (https=)
AU (1) AU2020312560A1 (https=)
BR (1) BR112022000417A2 (https=)
CA (1) CA3146798A1 (https=)
MX (1) MX2022000433A (https=)
WO (1) WO2021008840A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2603166A (en) * 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
EP4301394A1 (en) * 2021-03-03 2024-01-10 Synklino ApS Compositions for ex vivo organ care

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018954A2 (en) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
JP2009540842A (ja) * 2006-07-03 2009-11-26 イナゲン エイピーエス Ｃｍｖ感染に関連する疾患の治療のための免疫毒素
JP2012511921A (ja) * 2008-12-17 2012-05-31 ユニヴェルシテ ピエール エ マリ キューリ （パリ ６） Ｃｘ３ｃｒ１受容体モジュレータ及びその治療的使用
WO2019051204A1 (en) * 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2437201C (en) * 2001-02-02 2008-11-18 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
EP3262063B1 (en) * 2015-02-26 2021-09-22 Var2 Pharmaceuticals ApS Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018954A2 (en) * 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
JP2009540842A (ja) * 2006-07-03 2009-11-26 イナゲン エイピーエス Ｃｍｖ感染に関連する疾患の治療のための免疫毒素
JP2012511921A (ja) * 2008-12-17 2012-05-31 ユニヴェルシテ ピエール エ マリ キューリ （パリ ６） Ｃｘ３ｃｒ１受容体モジュレータ及びその治療的使用
WO2019051204A1 (en) * 2017-09-08 2019-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services SYNERGISTIC COMBINATION OF IL4, INTERFERON GAMMA AND INTERFERON ALPHA RECEPTOR AGENTS FOR USE IN THE TREATMENT OF OVARIAN CANCER

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF IMMUNOLOGY RESEARCH, vol. Volume 2017, Article ID 4069260, JPN6024020573, 2017, pages 1 - 12, ISSN: 0005339144 *
PNAS, vol. 112, no. 27, JPN6024020574, 2015, pages 8427 - 8432, ISSN: 0005339145 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 36, JPN6024020572, 2001, pages 33906 - 33914, ISSN: 0005339146 *

Also Published As

Publication number Publication date
MX2022000433A (es) 2022-04-25
US20220281933A1 (en) 2022-09-08
BR112022000417A2 (pt) 2022-03-03
EP3997107A1 (en) 2022-05-18
CN114206944A (zh) 2022-03-18
CA3146798A1 (en) 2021-01-21
WO2021008840A1 (en) 2021-01-21
AU2020312560A1 (en) 2022-03-03
KR20220032610A (ko) 2022-03-15

Similar Documents

Publication Publication Date Title
JP7212009B2 (ja) Ｃｘｃｒ４結合分子
JP5474535B2 (ja) Ｆｋｂｐ−ｌおよびその使用
KR101413480B1 (ko) Ｓｐａｒｃ 결합 펩티드와 이들의 용도
ES2582001T3 (es) Molécula que se une a antígeno y usos de la misma
CN108137671B (zh) 可溶性pdl-1分子
JP2022542886A (ja) プロテアーゼ活性化治療剤を含む組成物および方法
JP2013535462A (ja) 細胞内免疫
CN103501818A (zh) 用于高效及靶向递送治疗性分子至cxcr4细胞的方法和试剂
CN116323671A (zh) 具有增加的选择性的多靶向性双特异性抗原结合分子
WO2022022709A1 (zh) 一种SIRPα-Fc融合蛋白
CN116440285A (zh) 冠状病毒多肽类融合抑制剂的长效化的方法
JP2022540877A (ja) Ｃｍｖ感染に関連する疾患の治療のための融合毒素タンパク質
CN101914161B (zh) 抑制肿瘤生长的融合蛋白HGFα-Fc及其用途
US10376596B2 (en) Antimicrobial compositions comprising single domain antibodies and pseudomonas exotoxin
JP7668785B2 (ja) 融合タンパク質およびその使用
Zhang et al. A fusion protein of vimentin with Fc fragment inhibits Japanese encephalitis virus replication
KR101671069B1 (ko) 베타1 인테그린을 특이적으로 인지하는 항체 및 이의 용도
CN102176922A (zh) 包含结合于EBV(Epstein-Barr病毒)蛋白BARF1的抗体的药物组合物
WO2019167962A1 (ja) 高発現かつ高機能な二重特異性抗体
KR20130033273A (ko) 항 ｉｇｆ-1ｒ 단일클론 항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
RU2837537C1 (ru) Растворимый апф2, его слитый белок и способы их применения
CN119923414A (zh) 溶酶体降解
JP2024062917A (ja) ＨＬＡ－ＤＲ β鎖に対する新規な抗体およびその用途
KR20260024531A (ko) 암 배아 항원에 특이적으로 결합하는 항원 결합 단백질 또는 나노바디, 이를 포함하는 융합 단백질 및 이의 암 치료 용도
JPWO2013027658A1 (ja) 軟骨・骨破壊抑制剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230601

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241001